Immune cell army plus drug shows promise against tough melanoma
NCT ID NCT05176470
First seen Feb 25, 2026 · Last updated May 12, 2026 · Updated 7 times
Summary
This early-stage trial tests a two-pronged attack on advanced melanoma. First, doctors remove some of the patient's own immune cells from a tumor, grow them into a larger army in a lab (Lifileucel), and put them back. Second, they give the drug pembrolizumab to help those cells work better. The goal is to see if this combination is safe and can shrink tumors in people with stage IIIB-D or IV melanoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.